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Abstract
Purpose: Epigenetic alterations have been investigated as prognostic indicators in breast cancer but their translation into
clinical practice has been impeded by a lack of appropriate validation. We present the results of a meta-analysis of the
associations between RASSF1A promoter methylation status and both disease free survival (DFS) and overall survival (OS) in
female breast cancer.
Methods: Eligible studies were identified through searching the PubMed, Web of Science and Embase databases. Studies
were pooled and summary hazard ratios (HR) with corresponding confidence intervals (CIs) were calculated. Funnel plots
were also carried out to evaluate publication bias.
Results: A total of 1795 patients from eight studies were included in the meta-analysis. There are eight studies which
investigated DFS in 1795 cases. The relative hazard estimates ranged from 1.77–5.64 with a combined HR of 2.75 (95%CI
1.96–3.84). The HR of RASSF1A promoter methylation on DFS adjusted for other potential prognostic factors was 2.54
(95%CI 1.77–3.66). There has been five trials which analyzed the associations of RASSF1A promoter methylation status with
OS in 1439 patients. The hazard estimates ranged from 1.21–6.90 with a combined random-effects estimates of 3.47 (95%CI
1.44–8.34). OS reported in multivariate analysis was evaluated in four series comprising 1346 cases and the summarized
random-effects HR estimate was 3.35 (95%CI 1.14–9.85). Additionally, no publication bias was detected for both OS and DFS.
Conclusion: The results of this meta-analysis suggest that RASSF1A promoter hypermethylation confers a higher risk of
relapse and a worse survival in patients with breast cancer. Large prospective studies are now needed to establish the
clinical utility of RASSF1A promoter methylation.
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Introduction
Breast cancer (BC) is the most commonly diagnosed cancer and
the leading cause of cancer death in females worldwide,
accounting for 23% (1.38 million) of the total new cancer cases
and 14% (458,400) of the total cancer deaths in 2008 [1]. Because
of early detection and effective adjuvant medical treatments, the
survival rate of breast cancer has increased during the past
decades. However, breast cancer is remarkably heterogeneous in
histology and genetics, as well as in clinical behavior. Tradition-
ally, pathologic determinations of tumor size, lymph node status,
endocrine receptor status, histological grade, and human epider-
mal growth factor receptor 2 (HER2) expression have driven
prognostic predictions and, ultimately, adjuvant therapy recom-
mendations for patients with breast cancer [2]. Nonetheless, these
prognostic and predictive factors are relatively crude measures and
it poses a great challenge for clinicians regarding the choice of
optimum adjuvant treatment. It is of great importance to avoid
overtreatment in patients who only receive a modest benefit, while
suffering from more toxic side effects. On the other hand,
undertreatment or incorrect treatment has to be avoided as well.
Although the current well-established clinical and histological
factors and some other well-defined biological factors (e.g.,
hormone receptors and HER2 status) have been established and
are assessed routinely in therapy decision-making and evaluating
the prognosis, there are increasing concerns that these prognostic
determinants are limited in their ability to capture the diversity of
clinical behaviors of breast cancer and that they would be
insufficient to predict the response to specific treatment strategies
for individual patients. Recently, gene-expression-based prognostic
assays are being used to predict breast cancer outcomes, but their
prognostic validities are still undergoing evaluation [3]. Therefore,
research efforts continue to focus on identifying more sensitive and
specific indicators that could more reliably predict clinical
outcomes and enhance treatment options.
Bulks of epidemiological and experimental studies have verified
epigenetic and genetic changes involved in the development and
progression of breast cancer (see review [4]). Recently, changes in
the status of DNA methylation, known as epigenetic alterations,
have turned out to be one of the most common molecular
alterations in human malignancies, including breast cancer [5].
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frequently silenced by hypermethylation in breast cancer. Among
which, RAS-association domain family 1 (RASSF1A) is widely
investigated. RASSF1A (http://www.ncbi.nlm.nih.gov/
epigenomics/view/genome/56289?term=Rassf1), which is locat-
ed at 3p21.3, is functionally involved in cell cycle control,
microtubule stabilization, cellular adhesion, motility, and apopto-
sis [6]. Depletion of RASSF1A is reported to be associated with
accelerated mitotic progression, an elevated risk for chromosomal
defects, enhanced cellular motility, and increased tumor suscep-
tibility in knockout mice [7,8,9]. Epigenetic inactivation of
RASSF1A by hypermethylation of CpG islands in the promoter
region [NC_000075.5 (107,453,580–107,454,373)] is observed in
a considerable proportion of cancers and is associated with
clinicopathological factors in various types of cancers, including
breast cancer (see review [10]). Furthermore, RASSF1A promoter
hypermethylation was reported as a prognostic indicator in renal
cell carcinoma, non-small cell lung cancer, neuroblastoma,
melanoma, endometrial cancer and breast cancer [11–18]. All of
these findings suggested that it might play a pivotal role in the
development of human cancer.
Despite a number of individual studies performed in breast
cancer patients, the prognostic value of RASSF1A promoter
methylation status in breast cancer patient’s survival remains
controversial. Therefore, we performed a systematic review of the
literature with meta-analysis to obtain a more accurate evaluation
of its prognostic value in breast cancer.
Results
Study Selection and Characteristics
Fifty-eight relevant citations were identified for initial review
using search strategies as described previously. Of these, forty-six
were initially excluded after read the titles and abstracts (13 not
about breast cancer; 7 on cell lines; 11 review articles; 10 were on
tumor biological behavior; 5 with other gene methylation).
Investigators retrieved the remaining 12 citations for full text
evaluation. Upon further review, three articles were eliminated on
the basis of inadequate data for meta-analysis. Moreover, one was
excluded for overlapping publication [19]. Ultimately, the
systematic literature search yielded a total of 8 studies comprising
1795 patients for final analysis [15–18,20–24].
The characteristics of retained 8 studies are listed in Table 1.
The sample size of the included studies ranged from 78 to 670
patients (median sample size, 224 patients). The trials were
conducted in 7 countries (Portugal, USA, Saudi Arabia, Tunisia,
India, Greece, and Austria) and published between 2005 and
2011. There was 60.9% of BC patients had the methylated
RASSF1A allele with a frequency ranging from 19.6 to 87.0%
(median, 64.0%) in individual trials. The methylated RASSF1A
levels were detected using either methylation specific PCR (MSP)
[18,22,23] or quantitative methylation specific PCR (QMSP)
[15,17,20,21,24]. The corresponding primer sequences of PCR
are provided in a supplementary table (Table S1). DNA
methylation status of RASSF1A promoter was assessed in plasma
or tumor tissues. Except for one study that used fine-needle
aspirate washings [15]. A HR on DFS and OS could be extracted
from 5 and 8 of the studies, respectively. Most of the survival data
for breast cancer were available in the form of multivariate
analysis except for one study reported in univariate form (Kaplan–
Meier survival curve) [18].
Meta-analysis
The meta-analysis was carried out for the analyses of all studies
on OS, DFS and their subgroups. The main results of the meta-
analysis are summarized in Table 2. When all study populations
combined, dismal survival outcomes on BC patients with
hypermethylation of RASSF1A promoter were observed: for overall
survival, summary HR=3.47, 95%CI 1.44–8.34; I
2=72.70%,
random-effects model (Figure 1), and for disease free survival,
summary HR=2.75, 95% CI 1.96–3.84; I
2=0.00%, fixed-effects
model (Figure 2). Even by carrying out the meta-analysis using the
HRs from Cox regression models only, we still observed significant
pejorative impacts on OS (HR =3.35, 95% CI 1.14–9.85; test for
heterogeneity: I
2=76.20%) (Figure 3) and DFS (HR=2.54, 95%
CI 1.77–3.66; test for heterogeneity: I
2=0.00%) (Figure 4). Due to
strong heterogeneity existed in the trials aggregated for overall
survival, Galbraith plot was used to explore the heterogeneity. The
heterogeneity disappeared after omitting one trial by Cho et al.
(Chi-squared =0.38, p =0.945) [17].
In the subgroup analyses on overall survival, a significant
prognostic role of RASSF1A methylation status was detected in the
studies using MSP methods (HR=4.26, 95%CI 1.65–10.98).
However, no statistical significance reached in those using QMSP
(HR=3.28, 95%CI 0.94–11.50). When the differences of material
reported for detecting RASSF1A promoter methylation levels were
taken into consideration, the aggregated survival data showed an
unfavorable survival prognosis using plasma (HR 6.03, 95% CI
2.77–13.11), but not tissue samples.
In the subgroup analyses on disease-free survival, a subset of five
studies (1525 patients) reporting the DFS for breast cancer patients
using QMSP, and a subset of three studies (270 patients) reporting
the DFS using MSP were pooled separately. The summary HR
estimates for both groups showed inverse correlations with DFS
(HR=2.77, HR=2.71, respectively). In addition, there was no
difference when various materials used in detecting RASSF1A
methylation status. Furthermore, no evidence of heterogeneity
observed in these comparisons. These results suggest that breast
cancer patients with RASSF1A promoter hypermethylation have
a poor prognosis of relapse, irrespective of the detecting methods
and samples.
Assessment of Publication Bias
Visual assessment of the funnel plots provided no evidence of
overt publication bias for studies in either of the two outcomes.
Further evaluation using Egger’s linear regression test also failed to
reveal any evidence for significant publication bias in OS
(P=0.36) and DFS (P=0.34) study groups.
Discussion
For proper management of patients with cancer, accurate
prognostic and predictive factors are necessary. Such factors are
particularly important in breast cancer that has widely varying
outcomes and for which systemic adjuvant therapy may be
beneficial. Prognostic factors may help us to differentiate those
patients with indolent from those with more aggressive disease.
Patients with aggressive disease may then be candidates for
treatmentwithsystemicadjuvanttherapy,whilethosewithindolent
disease may be spared the toxic side-effects and costs of this
treatment. The accumulating evidence for epigenetic defects in
breast cancer may be potentially useful in cancer progression.
Aberrant DNA methylation of CpG islands within 5-prime of genes
occurs almostineverytype ofcancer and easy to measure. Potential
of gene-specific DNA methylation as a predictor of important
clinical features has been explored in a number of studies now.
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methylationwasreportedtobevaluableasaprognosticindicatorfor
breastcancer.Duetorelativelysmallsamplesofindividualstudyand
controversial conclusions, we performed this meta-analysis of the
literature to analyze whether RASSF1A hypermethylation could
readily be harnessed as clinically useful predictive biomarker for
breast cancer.
This is the first meta-analysis of published studies to evaluate the
association between RASSF1A promoter methylation and breast
cancer prognosis in 1795 cases. Our results using the summarized
HR of OS and DFS indicated that hypermethylation of RASSF1A is
associatedwithbothDFSandOS(pooledHRestimatesof2.75and
3.47 for DFS and OS, respectively). These effects were slightly
attenuatedbutstillsignificantinmultivariateanalyses(adjustedHRs
of 2.54and 3.35, respectively), showing that its effect is independent
Table 1. Baseline characteristics of eligible studies evaluating RASSF1A hypermethylation and OS or DFS in breast cancer patients.
First Author Year Country Methods M/N (%) N
Stage Grade Materials OS DFS
HR (95%CI) HR (95%CI)
Martins [15] 2011 Portugal QMSP 86 178 0–IV 1–3 fine-needle aspirate washings NA 2.53 (1.09–5.87)
Cho [17] 2011 USA QMSP 85.2 670 I–IV NA formalin fixed paraffin-embedded tissues1.21 (0.76–1.93) 1.77 (0.86–3.67)
Gobel [20] 2011 Austria QMSP 21.8 428 0–IV 1–3 peripheral blood-plasma 5.60 (2.10–14.50) 3.40 (1.60–7.30)
Kioulafa [18] 2009 Greece MSP 57 93 I–II 1–3 formalin fixed paraffin-embedded tissues4.31 (0.92–7.58) 3.47 (1.24–9.32)
Buhmeida [21] 2011 Saudi Arabia QMSP 65 100 I–IV 1–3 formalin fixed paraffin-embedded tissuesNA 5.64 (1.23–25.81)
Karray-Chouayekh [22] 2010 Tunisia MSP 87 78 I–IV 1–3 fresh-frozen specimens NA 7.33 (1.37–37.72)
Sharma [23] 2009 India MSP 63 100 I–III NA formalin fixed paraffin-embedded tissues4.05 (0.47–34.92) 1.80 (0.79–4.09)
Fiegl [24] 2005 Austria QMSP 19.6 148 I–III 1–3 peripheral blood-plasma 6.90 (1.90–25.90) 5.10 (1.30–19.80)
FFPE, formalin fixed paraffin-embedded; PBP, peripheral blood-plasma; FF, fresh-frozen; FNAW, fine-needle aspirate washings; MSP, methylation specific PCR; QMSP,
quantitative methylation specific PCR.
doi:10.1371/journal.pone.0036780.t001
Table 2. Main results of eligible studies evaluating RASSF1A hypermethylation and OS/DFS in breast cancer patients.
N. of studies/cases HR (95% CI) Heterogeneity
x
2 pI
2
Overall Survival (OS)
All studies
Fixed effects 5/1439 2.10 (1.45–3.03) 14.67 0.005 72.70%
Random effects 5/1439 3.47 (1.44–8.34) 14.67 0.005 72.70%
Cox regression model 4/1346 3.35 (1.14–9.85) 12.63 0.006 76.20%
Testing methods
QMSP 3/1246 3.28 (0.94–11.50) 12.14 0.002 83.5%
MSP 2/192 4.26 (1.65–10.98) 0.00 0.959 0.00%
Testing materials
Plasma 2/576 6.03 (2.77–13.11) 0.06 0.801 0.00%
Tissue samples 3/863 2.27 (0.82–6.27) 5.46 0.065 63.4%
Disease-Free Survival (DFS)
All studies
Fixed effects 8/1795 2.75 (1.96–3.84) 6.01 0.539 0.00%
Cox regression model 6/1624 2.54 (1.77–3.66) 4.28 0.51 0.00%
Testing methods
QMSP 5/1525 2.77 (1.84–4.15) 3.44 0.487 0.00%
MSP 3/270 2.71 (1.49–4.91) 2.57 0.277 22.1%
Testing materials
Plasma 2/576 3.74 (1.93–7.26) 0.26 0.610 0.00%
Tissue samples 5/1041 2.54 (1.57–4.13) 4.62 0.328 13.5%
MSP, methylation specific PCR; QMSP, quantitative methylation specific PCR.
doi:10.1371/journal.pone.0036780.t002
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36780Figure 1. Forest plot showing the association between RASSF1A methylation and overall survival (OS) of breast cancer. The summary
HR and 95% CIs were shown (according to the random-effects estimations).
doi:10.1371/journal.pone.0036780.g001
Figure 2. Forest plot showing the association between RASSF1A methylation and disease-free survival (DFS) of breast cancer. The
summary HR and 95% CIs were shown (according to the fixed-effects estimations).
doi:10.1371/journal.pone.0036780.g002
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36780Figure 3. Forest plot showing the association between RASSF1A methylation and overall survival (OS) of breast cancer calculating
from the data of multivariate Cox regression analyses.
doi:10.1371/journal.pone.0036780.g003
Figure 4. Forest plot showing the association between RASSF1A methylation and disease-free survival (DFS) of breast cancer
calculating from the data of multivariate Cox regression analyses.
doi:10.1371/journal.pone.0036780.g004
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of other biological variables on multivariate analysis.
When the five studies reported the HR of overall survival were
pooled, a considerable degree of interstudy heterogeneity was
noticed (I
2=72.7%). We applied Galbraith plot which is visualized
in identifying the heterogeneous studies to explore the heteroge-
neity. When one study by Cho et al. was excluded, the hazard size
remains significant but the heterogeneity disappeared. The
heterogeneity was probably due to the difference in the baseline
characteristics of patients (age, tumor stage, race or country), the
detecting methods, testing materials, the duration of follow-up or
others. For example, when we stratified them according to
detecting methods, heterogeneity disappeared in MSP subgroup.
Strong heterogeneity still existed in quantitative methylation-
specific PCR subgroup. Some techniques features regarding
QMSP may partially explain this heterogeneity. First, lack of
clear hypermethylation cut-off definition, it should be made about
the cut-off value of RASSF1A methylation level for increased
survival risk. To date, the researchers use median or self-defined
value in their laboratory as the cut-off value and the accurate value
was different. In addition, testing materials may also contribute to
the heterogeneity, in this subgroup, methylation level detecting
using tissue samples was marked (I
2=63.4%). We postulated that
the timing from resection to fixation or the process of fixation itself
may potentially alter methylation status in paraffin-embedded
tumors. One study observed that methylation status varied when
different fixation techniques used [25]. We addressed the issue of
heterogeneity by a rigorous methodological approach that used
a random-effects model for more conservative estimates. Never-
theless, there is no definitive explanation for the heterogeneity.
Some limitations of this meta-analysis should be discussed. First,
this analysis was performed at the study level, which limited ability
to explore the potential for confounding by various demographic
and clinical factors (e.g., ethnicity, hormone receptor status,
disease stage, differentiation and treatment regimes). Second, this
study was predominately based on the findings of observational
studies, which inherently contain greater potential for confounding
than randomized controlled trials. Third, potential risk bias was
a concern, as published studies are often positive and so the
omission of unpublished studies may lead to exaggeration of the
summary HR. Although publication bias evaluation did not
suggest any bias in the pooled OS and DFS studies, we identified
studies only from limited databases, the total number of included
studies and the total sample size were relatively small; which might
influence the validity of our analysis to some extent. Fourth, the
quality of pooled studies influences the level of confidence of meta-
analysis remarkably. Published articles often lack sufficient in-
formation to allow adequate assessment of the quality of the study
or the generalisability of the study results. So REMARK criteria
were recommended when reporting tumor markers [26]. Only one
involved study reported the prognostic role of RASSF1A methyl-
ation in BC using REMARK criteria [17]. Finally, most of studies
included in the pooled analyses of breast cancer outcomes were
carried out in European populations, it is possible that the results
of these analyses are not readily generalizable to other populations.
Because of these limitations existing in the identified studies and
the current meta-analysis, our results should be interpreted with
caution and likewise, the conclusions of this meta-analysis should
also be drawn carefully.
In conclusion, hypermethylation of RASSF1A promoter was
found to be independently associated with decreased survival of
breast cancer patients. The promoter methylation of the RASSF1A
gene is potentially useful biomarker for predicting prognosis in
breast cancer. Large studies, both observational cohorts and
clinical trials, are now urgently needed to test whether hyper-
methylation of RASSF1A can provide prognostic information in
addition to currently used standards and also to establish if it has
clinical utility.
Materials and Methods
Publication Selection
A comprehensive literature search was carried out by two
independent reviewers (Jiang Y and Cui L) using the PubMed,
Web of Science and Embase databases. The search ended on 9
September 2011. The following keywords were used in various
combinations: ‘breast cancer’, ‘biomarkers’, ‘molecular markers’,
‘survival’, ‘prognosis’, ‘RAS-association domain family 19 and
‘RASSF1A’. The search was performed without langue restriction.
Reference lists from relevant primary studies and review articles
were also checked for additional relevant publications. To be
eligible for inclusion, studies had to meet the following criteria: (1)
evaluating the association between RASSF1A promoter methyla-
tion status and the prognosis of breast cancer patients, e.g., disease
free survival (DFS) and/or overall survival (OS); (2) hazard ratio
(HR) for OS or DFS according to RASSF1A methylation status
either had to be reported or could be calculated from the data
presented; (3) studies should be with full text not only abstracts for
relevant information extraction; (4) when the same patient
population reported in several publications, only the most recent
report or the most complete one was included in this analysis to
avoid overlapping between cohorts.
Definitions and Data Extraction
Overall survival was defined as the interval between the medical
treatment (including surgical excision, chemotherapy or radio-
therapy) and the death of patients or the last observation. Disease
free survival was measured from the date of treatment until the
detection of recurrence or the last follow-up assessment. The
following data from all eligible publications was extracted
respectively by two reviewers (Cui L and Chen WD) with
a standardized data extraction form: first author’s surname, year
of publication, patient source, sample size, disease stage, tumor
grade, methylation status detecting method, positive ratio, and
prognostic outcomes of interest (DFS and OS, including the
information whether the outcomes were tested by multivariate
analysis). Disagreements were resolved by discussion.
Statistical Analysis
Meta-analysis techniques were used to compute a summary
estimate of the hazard ratio (HR) and 95% confidence intervals
(CIs) for recurrence or death with breast cancer. Survival outcome
data were synthesized using the time-to-event HR as the effective
measure. When HR was not provided directly, estimated value
was derived indirectly from other presented data using the
methods described by Tierney et al. [27]. Moreover, when
univariate and multivariate analyses of OS and/or DFS were
both available, the latter was selected to be combined because
survival response variable is influenced by multiple factors.
Heterogeneity between the studies was tested using Q-statistics.
It was considered statistically significant if p value less than 0.10
and was also quantified using the I
2 metric (I
2,25%, no
heterogeneity; I
2=25–50%, moderate heterogeneity; and
I
2.50%, strong heterogeneity) [28,29]. If the heterogeneity was
existed, we used a random-effects model in place of a fixed-effects
model and the Galbraith plot was used to provide a graphical
display to get a visual impression of the amount of heterogeneity
from a meta-analysis [30]. By convention, an observed HR.1
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methylation. This impact of RASSF1A on survival was considered
as statistically significant if the corresponding 95% CI for the
summary HR did not overlap 1 unit. Publication bias was assessed
by funnel plots and Egger’s linear regression. All p values were two
sided. Statistical calculations were all performed using STATA
version 11.0, College Station TX.
Supporting Information
Table S1 The primer sequences of detecting RASSF1A
promoter methylation status of the eligible studies.
(DOC)
Author Contributions
Conceived and designed the experiments: JY CL. Performed the
experiments: JY CDW. Analyzed the data: CL SSH. Contributed
reagents/materials/analysis tools: JY. Wrote the paper: DLD JY.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer
statistics. CA Cancer J Clin 61: 69–90.
2. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, et al. (2010) Breast
cancer prognostic classification in the molecular era: the role of histological
grade. Breast Cancer Res 12: 207.
3. Kim C, Paik S (2010) Gene-expression-based prognostic assays for breast cancer.
Nat Rev Clin Oncol 7: 340–347.
4. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358: 1148–1159.
5. Muller HM, Fiegl H, Widschwendter A, Widschwendter M (2004) Prognostic
DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci 1022:
44–49.
6. Agathanggelou A, Cooper WN, Latif F (2005) Role of the Ras-association
domain family 1 tumor suppressor gene in human cancers. Cancer Res 65:
3497–3508.
7. Dallol A, Cooper WN, Al-Mulla F, Agathanggelou A, Maher ER, et al. (2007)
Depletion of the Ras association domain family 1, isoform A-associated novel
microtubule-associated protein, C19ORF5/MAP1S, causes mitotic abnormal-
ities. Cancer Res 67: 492–500.
8. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, et al. (2005) Tumor
susceptibility of Rassf1a knockout mice. Cancer Res 65: 92–98.
9. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, et al. (2004) The tumour
suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex.
Nat Cell Biol 6: 129–137.
10. Hesson LB, Cooper WN, Latif F (2007) The role of RASSF1A methylation in
cancer. Dis Markers 23: 73–87.
11. Wang J, Wang B, Chen X, Bi J (2011) The prognostic value of RASSF1A
promoter hypermethylation in non-small cell lung carcinoma: a systematic
review and meta-analysis. Carcinogenesis 32: 411–416.
12. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, et al. (2009)
CpG island methylator phenotype predicts progression of malignant melanoma.
Clin Cancer Res 15: 1801–1807.
13. Jo H, Kim JW, Kang GH, Park NH, Song YS, et al. (2006) Association of
promoter hypermethylation of the RASSF1A gene with prognostic parameters
in endometrial cancer. Oncol Res 16: 205–209.
14. Misawa A, Tanaka S, Yagyu S, Tsuchiya K, Iehara T, et al. (2009) RASSF1A
hypermethylation in pretreatment serum DNA of neuroblastoma patients:
a prognostic marker. Br J Cancer 100: 399–404.
15. Martins AT, Monteiro P, Ramalho-Carvalho J, Costa VL, Dinis-Ribeiro M, et
al. (2011) High RASSF1A promoter methylation levels are predictive of poor
prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer
Res Treat 129: 1–9.
16. Kawai Y, Sakano S, Suehiro Y, Okada T, Korenaga Y, et al. (2010) Methylation
level of the RASSF1A promoter is an independent prognostic factor for clear-
cell renal cell carcinoma. Ann Oncol 21: 1612–1617.
17. Cho YH, Shen J, Gammon MD, Zhang YJ, Wang Q, et al. (2011) Prognostic
significance of gene-specific promoter hypermethylation in breast cancer
patients. Breast Cancer Res Treat.
18. Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES (2009)
Prognostic significance of RASSF1A promoter methylation in operable breast
cancer. Clin Biochem 42: 970–975.
19. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, et al. (2003)
DNA methylation in serum of breast cancer patients: an independent prognostic
marker. Cancer Res 63: 7641–7645.
20. Gobel G, Auer D, Gaugg I, Schneitter A, Lesche R, et al. (2011) Prognostic
significance of methylated RASSF1A and PITX2 genes in blood- and bone
marrow plasma of breast cancer patients. Breast Cancer Res Treat.
21. Buhmeida A, Merdad A, El-Maghrabi J, Al-Thobaiti F, Ata M, et al. (2011)
RASSF1A Methylation is Predictive of Poor Prognosis in Female Breast Cancer
in a Background of Overall Low Methylation Frequency. Anticancer Res 31:
2975–2981.
22. Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T,
et al. (2010) Aberrant methylation of RASSF1A is associated with poor survival
in Tunisian breast cancer patients. J Cancer Res Clin Oncol 136: 203–210.
23. Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, et al. (2009) Prognostic
relevance of promoter hypermethylation of multiple genes in breast cancer
patients. Cell Oncol 31: 487–500.
24. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, et al. (2005)
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant
therapy in cancer patients. Cancer Res 65: 1141–1145.
25. Hamilton MG, Roldan G, Magliocco A, McIntyre JB, Parney I, et al. (2011)
Determination of the methylation status of MGMT in different regions within
glioblastoma multiforme. J Neurooncol 102: 255–260.
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006)
REporting recommendations for tumor MARKer prognostic studies (RE-
MARK). Breast Cancer Res Treat 100: 229–235.
27. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical
methods for incorporating summary time-to-event data into meta-analysis.
Trials 8: 16.
28. DerSimonian R (1996) Meta-analysis in the design and monitoring of clinical
trials. Stat Med 15: 1237–1248; discussion 1249–1252.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring
inconsistency in meta-analyses. BMJ 327: 557–560.
30. Bax L, Ikeda N, Fukui N, Yaju Y, Tsuruta H, et al. (2009) More than numbers:
the power of graphs in meta-analysis. Am J Epidemiol 169: 249–255.
RASSF1A Methylation and Breast Cancer Survival
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36780